SCHEMBL3751266

SCHEMBL3751266

N#CC(c1ccnc(OCc2ccnc(N3CCOCC3)c2)n1)c1nc2ccccc2s1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 11/20 0.74
MAPK9 P45984 10/20 0.74
MAPK8 P45983 2/20 0.74
HCRTR1 O43613 1/20 0.39
HCRTR2 O43614 1/20 0.39
RAB9A P51151 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 2/20 0.38
KDM4E B2RXH2 1/20 0.36
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
DRD3 P35462 1/20 0.36
ALDH1A1 P00352 3/20 0.35
NPSR1 Q6W5P4 2/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SORD Q00796 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3748095 0.92 MAPK10 (0.69) MAPK10MAPK9MAPK8RAB9ASMN1; SMN2
SCHEMBL3745112 0.86 MAPK10 (0.71) MAPK10MAPK9MAPK8RAB9ASMN1; SMN2
SCHEMBL3747858 0.86 MAPK10 (0.86) MAPK10MAPK9MAPK8RAB9ASMN1; SMN2
Bentamapimod SCHEMBL29423429 0.85 MAPK10 (1.00) MAPK10MAPK9MAPK8RAB9ASMN1; SMN2
Bentamapimod SCHEMBL30197744 0.85 MAPK10 (1.00) MAPK10MAPK9MAPK8RAB9ASMN1; SMN2
Bentamapimod SCHEMBL2878382 0.85 MAPK10 (1.00) MAPK10MAPK9MAPK8RAB9ASMN1; SMN2
Bentamapimod SCHEMBL29350260 0.85 MAPK10 (1.00) MAPK10MAPK9MAPK8RAB9ASMN1; SMN2
SCHEMBL2881240 0.81 MAPK10 (0.88) MAPK10MAPK9MAPK8RAB9ASMN1; SMN2
SCHEMBL1518907 0.81 MAPK10 (1.00) MAPK10MAPK9MAPK8RAB9ASMN1; SMN2
SCHEMBL3742425 0.81 MAPK10 (0.75) MAPK10MAPK9MAPK8SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7838522-B2 Benzothiazole formulations and use thereof ARES TRADING S.A. (CH) 2010-11-23 US disclosed
US-7838522-B2 Benzothiazole formulations and use thereof ARES TRADING S.A. (CH) 2010-11-23 US disclosed
US-7838522-B2 Benzothiazole formulations and use thereof ARES TRADING S.A. (CH) 2010-11-23 US disclosed
EP-1812072-B1 BENZOTHIAZOLE FORMULATIONS AND USE THEREOF ARES TRADING SA (CH) 2008-10-22 EP disclosed
US-20080051397-A1 Benzothiazole Formulations and Use Thereof ARES TRADING S.A. (CH) 2008-02-28 US disclosed
US-20080051397-A1 Benzothiazole Formulations and Use Thereof ARES TRADING S.A. (CH) 2008-02-28 US disclosed
US-20080051397-A1 Benzothiazole Formulations and Use Thereof ARES TRADING S.A. (CH) 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051397-A1 Benzothiazole Formulations and Use Thereof MGLL, MBOAT4, MBOAT1 MAPK10 3176/4885MAPK9 3960/4885MAPK8 4361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.